v3.20.2
Stockholders' Equity
9 Months Ended
Sep. 30, 2020
Stockholders' Equity Note [Abstract]  
Stockholders' Equity

Note 3 — Stockholders’ Equity:

 

Common Stock

 

On July 30, 2020, the Company completed an underwritten public offering of its common stock, par value $0.001 per share, which yielded net proceeds of approximately $21.3 million. The public offering was made pursuant to an underwriting agreement with SunTrust Robinson Humphrey, Inc. and JMP Securities LLC (collectively, the “Underwriters”), relating to the issuance and sale of an aggregate of 5,111,110 shares of common stock, including 666,666 shares of common stock pursuant to the full exercise of the Underwriters’ option, at a public offering price of $4.50 per share. The offering was made pursuant to the Company’s effective registration statement on Form S-3 Registration Statement No. 333-223562 previously filed with and declared effective by the SEC and a prospectus supplement and accompanying prospectus filed with the SEC.

 

The Company is a party to a sales agreement with B. Riley dated March 9, 2018 for the sale of up to $14.7 million of the Company’s common stock under the Company’s ATM program, pursuant to a registration statement filed on March 9, 2018 for an aggregate of $70.0 million of the Company’s securities, which became effective on April 16, 2018. In November 2018, the ATM program amount was increased by $25.0 million. Under the ATM program, the Company may issue and sell common stock from time to time through B. Riley acting as agent, subject to limitations imposed by the Company and subject to B. Riley’s acceptance, such as the number or dollar amount of shares registered under the registration statement to which the offering relates. B. Riley is entitled to a commission of up to 3% of the gross proceeds from the sale of common stock sold under the ATM program. On August 31, 2020, the Company filed a prospectus supplement which allocated to the ATM program the remaining balance of its current shelf registration statement of approximately $7.3 million. The $7.3 million under the prospectus supplement, plus the $2.1 million already available under the ATM program, resulted in a total of approximately $9.4 million available to be sold under the Company’s ATM program. At September 30, 2020, the Company has approximately $8.7 million available under its ATM program (see Note 7 for subsequent event sales under the ATM program).

 

During the nine months ended September 30, 2020 and 2019, the Company sold 477,721 and 1,768,012 shares of common stock under the ATM program, respectively, and realized net proceeds of approximately $3.0 million and $15.2 million, respectively.

 

During the nine months ended September 30, 2020 and 2019, the Company issued an aggregate of 91,500 and 1,944,707 shares of its common stock upon exercise of warrants, respectively, resulting in net proceeds to the Company of $0.4 million and $8.7 million, respectively.

 

During the nine months ended September 30, 2020 and 2019, the Company issued an aggregate of 2,490 and 19,425 shares of its common stock, respectively, upon the vesting of restricted stock units issued to the Company’s board of directors.

 

During the nine months ended September 30, 2019, the Company issued an aggregate of 36,590 shares of its common stock upon exercise of stock options, resulting in net proceeds of $117,000 to the Company. No stock options were exercised during the nine months ended September 30, 2020.

 

Preferred Stock

 

The Company is authorized to issue up to 2,000,000 shares of preferred stock in one or more series without stockholder approval. The Company’s board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. Of the 2,000,000 shares of preferred stock authorized, the Company’s board of directors has designated (all with par value of $0.001 per share) the following:

 

   As of September 30, 2020   As of December 31, 2019 
   Preferred Shares Outstanding   Liquidation Preference (Per Share)   Total Liquidation Preference   Preferred Shares Outstanding   Liquidation Preference (Per Share)   Total Liquidation Preference 
Series C-3   52,000   $10.00000   $520,000    52,000   $

10.00000

   $520,000 
Series E   89,623   $49.20000   $4,409,452    89,623   $

49.20000

   $4,409,452 
Series G   100,000   $187.36452   $18,736,452    100,000   $187.36452   $18,736,452 
                               
Total   241,623        $23,665,904    241,623        $23,665,904 

 

Stock Options

 

During the nine months ended September 30, 2020, the Company granted ten-year qualified and non-qualified stock options covering an aggregate of 1,086,984 shares of the Company’s common stock under the 2019 Stock Incentive Plan. The weighted average exercise price of these options is $5.11 per share.

 

During the three and nine months ended September 30, 2020, total compensation expense for stock options issued to employees, directors, officers and consultants was $611,000 and $1,973,000, respectively, and $519,000 and $1,835,000 for the three and nine months ended September 30, 2019, respectively.

 

As of September 30, 2020, there was approximately $3,719,000 in total unrecognized compensation expense related to stock options granted, which expense will be recognized over an expected remaining weighted average period of 1.7 years.

 

The fair value of each stock option award estimated on the grant date is determined using the Black-Scholes option pricing model with the following assumptions, for the nine months ended September 30, 2020:

 

Expected term, years   5 - 10
Volatility   102.73% - 107.87%
Dividend yield   0.0%
Risk-free interest rate   0.27% - 1.67%
Weighted average grant date fair value of options granted during the period   $3.58

 

The Company estimated the expected term of the stock options granted based on anticipated exercises in future periods. The expected term of the stock options granted to consultants is based upon the full term of the respective option agreements. The expected stock price volatility for the Company’s stock options is calculated based on the historical volatility since the initial public offering of the Company’s common stock in March 2010. The expected dividend yield of 0.0% reflects the Company’s current and expected future policy for dividends on the Company’s common stock. To determine the risk-free interest rate, the Company utilized the U.S. Treasury yield curve in effect at the time of grant with a term consistent with the expected term of the Company’s awards which is 5 years for employees and 10 years for non-employees.

 

The following table summarizes the Company’s stock options activity and related information for the nine months ended September 30, 2020:

 

   Shares   Weighted Average
Exercise Price
   Weighted Average
Remaining Contractual Term (Years)
  

Aggregate Intrinsic Value

 
Outstanding at beginning of period   1,376,394   $8.98    6.8   $

799,379

 
Granted   1,086,984   $5.11        $1,070,717 
Forfeited   (28,800)  $9.01        $
-
 
Expired   (6,891)  $12.53        $
-
 
Exercised   
-
    
-
        $
-
 
Outstanding at end of period   2,427,687   $7.23    7.5   $1,870,096 
Exercisable at end of period   1,251,023   $8.53    5.9   $827,570 

 

The aggregate intrinsic value is calculated as the difference between the exercise prices of the underlying options and the quoted closing price of the common stock of the Company at the end of the reporting period for those options that have an exercise price below the quoted closing price. There were no stock options exercised during the nine months ended September 30, 2020.

 

Restricted Stock Units

 

During the nine months ended September 30, 2020, the Company issued an aggregate of 2,490 shares of its common stock upon the vesting of RSUs issued to the Company’s board of directors.

 

During the three and nine months ended September 30, 2020, compensation expense recorded for the RSUs was $400 and $11,000, respectively, and $52,000 and $151,000 for the three and nine months ended September 30, 2019, respectively. As of September 30, 2020, all outstanding RSUs had vested and compensation expense had been fully recognized.

 

Warrants

 

During the nine months ended September 30, 2020 and 2019, the Company issued an aggregate of 91,500 and 1,944,707 shares of its common stock upon exercise of warrants, respectively, resulting in net proceeds to the Company of $412,000 and $8,658,000, respectively.

 

As of September 30, 2020, there were 183,148 outstanding warrants with a weighted average exercise price of $4.96 per share and a weighted average remaining contractual life of 1.86 years.